Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis

Oncogene

Volumn 26, Issue 12, 2007, Pages 1723-1730

  Rojas, P ^a   Cadenas, M B ^b   Lin, P C ^c   Benavides, F ^a   Conti, C J ^a   Rodriguez Puebla, M L ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cyclin D2; Cyclin D3; DMBA; Keratinocytes; Papillomas; Skin

Indexed keywords

CYCLIN D2; CYCLIN D3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; KERATINOCYTE; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CYCLINS; IMMUNOPRECIPITATION; MICE; MICE, TRANSGENIC; SKIN NEOPLASMS;

MUS;

EID: 33947221512     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209970     Document Type: Article

References (33)

1. Bartkova J, Lukas J, Strauss M, Bartek J. (1998). Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 17: 1027-1037.
2. Cheung TH, Yu MM, Lo KW, Yim SF, Chung TK, Wong YF. (2001). Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett 166: 199-206.
3. Ciemerych MA, Kenney AM, Sicinska E, Kalaszczynska I, Bronson RT, Rowitch DH et al. (2002). Development of mice expressing a single D-type cyclin. Genes Dev 16: 3277-3289.
4. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat A, Marie J et al. (1995). Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85: 2870-2876.
5. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R et al. (1995). Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90: 43-50.
6. Farkas T, Hansen K, Holm K, Lukas J, Bartek J. (2002). Distinct phosphorylation events regulate p130- and p107-mediated repression of E2F-4. J Biol Chem 277: 26741-26752.
7. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A et al. (2002). Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8: 729-733.
8. Fujii M, Ishiguro R, Yamashita T, Tashiro M. (2001). Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue. Cancer Lett 172: 187-192.
9. Hedberg Y, Roos G, Ljungberg B, Landberg G. (2002). Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta Oncol 41: 175-181.
10. Houldsworth J, Reuter V, Bosl G, Chaganti R. (1997). Aberrant expression of cyclin D2 in an early event in human male germ cell tumorigenesis. Cell Growth Differ 8: 292-299.
11. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N. (2001). Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res 21: 1043-1048.
12. Kiess M, Gill R, Hamel P. (1995). Expression of the positive regulator of cell cycle progression, cyclin D3, is reduced during differentiation of myoblasts into quiescent myotubes. Oncogene 10: 159-166.
13. Leng X, Noble M, Adams PD, Qin J, Harper JW. (2002). Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol Cell Biol 22: 2242-2254.
14. Mariappan I, Parnaik VK. (2005). Sequestration of pRb by cyclin D3 causes intranuclear reorganization of lamin A/C during muscle cell differentiation. Mol Biol Cell 16: 1948-1960.
15. Matsushine H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. (1994). D-type cyclin-dependent kinases activity in mammalian cells. Mol Cell Biol 14: 2066-2076.
16. Meyerson M, Harlow E. (1994). Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086.
17. Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML. (2004). Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23: 1863-1873.
18. Pruneri G, Pignataro L, Valentini S, Fabris S, Maisonneuve P, Carboni N et al. (2005). Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res 11: 242-248.
19. Ramirez A, Bravo A, Jorcano J, Vidal M. (1994). Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 58: 53-64.
20. Robles A, Rodriguez-Puebla M, Glick A, Trempus C, Hansen L, Sicinski P et al. (1998). Reduced skin tumor development in cyclin D1 deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12: 2469-2474.
21. Rodriguez-Puebla ML, LaCava M, Conti C. (1999). Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development. Cell growth Diff 10: 467-472.
22. Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Jonhson DG, Conti CJ. (1998a). Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene 17: 2251-2258.
23. Rodriguez-Puebla ML, LaCava M, Miliani de Marval PL, Jorcano JL, Richie E, Conti CJ. (2000). Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol 157: 1039-1050.
24. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. (2002). cdk4 deficiency inhibits skin tumor development but does not affect keratinocyte proliferation. Am J Pathol 161: 405-411.
25. Rodriguez-Puebla ML, Robles AI, Johnson DG, LaCava M, Conti CJ. (1998b). Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13- acetate treatment of mouse skin: an in vivo model for cell cycle regulation. Cell Growth Differ 9: 31-39.
26. Sherr CJ. (1995). D-type cyclins. Trends Biochem Sci 20: 187-190.
27. Sherr CJ, Roberts JM. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 10: 1491-1502.
28. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q et al. (2003). Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4: 451-461.
29. Sicinski P, Donaher J, geneg Y, Parker S, Garder H, Park M et al. (1996). Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384: 470-474.
30. Sicinski P, Donaher J, Parker S, Li T, Fazeli A, Gardener H et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630.
31. Skapek SX, Rhee J, Spicer DB, Lassar AB. (1995). Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267: 1022-1024.
32. Wong SC, Chan JK, Lee KC, Hsiao WL. (2001). Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis and tumour progression in invasive ductal carcinoma of the breast. J Pathol 194: 35-42.
33. Zhang S-Y, Liu S-C, Goodrow T, Morris R, Klein-Szanto AJP. (1997). Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinogen 18: 142-152.